Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Northwestern Ophthalmic Institute S.C. Research to Prevent Blindness |
---|---|
Information provided by: | Northwestern Ophthalmic Institute S.C. |
ClinicalTrials.gov Identifier: | NCT00675207 |
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.
Condition | Intervention | Phase |
---|---|---|
Primary Open Angle Glaucoma Ocular Hypertension |
Drug: Brimonidine purite 0.15% Drug: Dorzolamide 2% Drug: Brinzolamide 1% |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Investigator), Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs |
Enrollment: | 120 |
Study Start Date: | January 2006 |
Study Completion Date: | July 2007 |
Primary Completion Date: | July 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
Brimonidine purite 0.15%
|
Drug: Brimonidine purite 0.15%
A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
|
2: Active Comparator
Dorzolamide 2%
|
Drug: Dorzolamide 2%
A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
|
3: Active Comparator
Brinzolamide 1%
|
Drug: Brinzolamide 1%
A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
|
Ages Eligible for Study: | 41 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Illinois | |
Northwestern Ophthalmic Institute S.C. | |
Glenview, Illinois, United States, 60026 |
Principal Investigator: | Thomas E. Bournias, MD | Northwestern Ophthalmic Institute S.C. |
Responsible Party: | Northwestern Ophthalmic Institute S.C. ( Thomas E. Bournias ) |
Study ID Numbers: | NWOIADJ 2006 |
Study First Received: | May 6, 2008 |
Last Updated: | May 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00675207 |
Health Authority: | United States: Institutional Review Board |
glaucoma ocular hypertension adjunctive treatment prostaglandin prostaglandin analog brimonidine |
dorzolamide brinzolamide alpha agonist carbonic anhydrase inhibitor intraocular pressure |
Brinzolamide Glaucoma Eye Diseases Glaucoma, Open-Angle Vascular Diseases |
Dorzolamide Brimonidine Hypertension Ocular Hypertension |
Neurotransmitter Agents Adrenergic alpha-Agonists Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Enzyme Inhibitors Cardiovascular Agents |
Antihypertensive Agents Adrenergic Agonists Pharmacologic Actions Carbonic Anhydrase Inhibitors Therapeutic Uses Cardiovascular Diseases |